Naltrexone in the Treatment of Alcohol Dependence

Cited by (618)

Items 301–400 of 618

1. Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers
   Dena Davidson, Chandan Saha, Stephanie L. Scifres, Joanne Daggy, Sean O’Connor, Christopher Selzer · 2004 · Addictive Behaviors
2. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence
   Gupta, Manushree, Verma, Pankaj, Rastogi, Rajesh, Arora, Sheetal, Elwadhi, Deeksha · 2017 · The American Journal of Drug and Alcohol Abuse
3. Food Addiction
   Haley Krupa, Ashley Nicole Gearhardt, Anne Lewandowski, Nicole M. Avena · 2024 · Brain Sciences
4. Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof‐of‐Concept Study
   Angela Christina Busch, Meenakshi S. Denduluri, Joseph E. Glass, Scott Hetzel, Shalu P. Gugnani, Michele Gassman, Dean D. Krahn, Brienna M. F. Deyo, Randall Brown · 2017 · Alcoholism Clinical and Experimental Research
5. Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages
   Astrid E. van der Velde · 2005 · Journal of Clinical Investigation
6. Efficacy of Extended-Release Naltrexone in Patients with Relatively Higher Severity of Alcohol Dependence
   Helen M. Pettinati, Bernard L. Silverman, John J Battisti, Robert F. Forman, Edward Ernest Schweizer, David R. Gastfriend · 2011 · Alcoholism Clinical and Experimental Research
7. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
   Barbara J. Mason · 2005 · Journal of Studies on Alcohol Supplement
8. FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study
   Patrick Bach, Georg Weil, Enrico Pompili, Sabine Hoffmann, Derik Hermann, Sabine Vollstädt‐Klein, Falk Kiefer, Karl F Mann, Wolfgang H. Sommer · 2021 · European Archives of Psychiatry and Clinical Neuroscience
9. Dissociation of μ‐opioid receptor and CRF ‐ R 1 antagonist effects on escalated ethanol consumption and mPFC serotonin in C 57 BL /6 J mice
   Lara S. Hwa, Akiko Shimamoto, Tala M. Kayyali, Kevin J. Norman, Rita J. Valentino, Joseph F. DeBold, Klaus A. Miczek · 2014 · Addiction Biology
10. Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent
    Laith Naser AL-Eitan, Saied A. Jaradat, Steve Su, Guan K. Tay, Hulse · 2012 · Pharmacogenomics and Personalized Medicine
11. PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES
    Michael A. Dawes · 2004 · Alcohol and Alcoholism
12. Mutation screen of the GAD2 gene and association study of alcoholism in three populations
    Jaakko Lappalainen, Evgeny M. Krupitsky, Henry R. Kranzler, Xingguang Luο, Mikhail Remizov, С. Н. Пчелина, Anastaisa Taraskina, Edwin E. Zvartau, Pirkko K. Räsänen, Taru Mäkikyrö et al. · 2006 · American Journal of Medical Genetics Part B Neuropsychiatric Genetics
13. CLINICAL STUDY: Does naltrexone affect craving in abstinent opioid‐dependent patients?
    Dijkstra, Boukje A. G., De Jong, Cor A. J., Bluschke, Sarah M., Krabbe, Paul F. M., Van Der Staak, Cees P. F. · 2007 · Addiction Biology
14. Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity
    Roberta Agabio, Hugo López‐Pelayo, Pol Bruguera, San‐Yuan Huang, Salvatore Sardo, Marta Peciña, Evgeny M. Krupitsky, Garrett M. Fitzmaurice, Zhicheng Lin · 2024 · Pharmacological Research
15. Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, “Naltrexone in the Treatment of Alcoholism”
    John Harrison Krystal, Ralitza V. Gueorguieva, Joyce A. Cramer, Joseph F. Collins, Robert Alan Rosenheck, The VA CSP No. 425 Study Team · 2007 · Alcoholism Clinical and Experimental Research
16. An investigator-blinded, randomized study to compare the efficacy of combined CBT for alcohol use disorders and social anxiety disorder versus CBT focused on alcohol alone in adults with comorbid disorders: the Combined Alcohol Social Phobia (CASP) trial protocol
    Andrew Baillie, Claudia Sannibale, Lexine Ann Stapinski, Maree Teesson, Ronald M. Rapee, Paul Haber · 2013 · BMC Psychiatry
17. The Role of Psychosocial Treatments in Pharmacotherapy for Alcoholism
    Mary Elizabeth McCaul, Nancy M. Petry · 2003 · American Journal on Addictions
18. Effect of Lysine at C-Terminus of the Dmt-Tic Opioid Pharmacophore
    Gianfranco Balboni, Valentina Onnis, Cenzo Congiu, Margherita Zotti, Yusuke Sasaki, Akihiro Ambo, Sharon D. Bryant, Yunden Jinsmaa, Lawrence H. Lazarus, Claudio Trapella et al. · 2006 · Journal of Medicinal Chemistry
19. Patterns of Dispensed Disulfiram and Naltrexone for Alcoholism Treatment in a Veteran Patient Population
    John A. Hermos, Melissa Young, DAVID R. GAGNON, Louis D. Fiore · 2004 · Alcoholism Clinical and Experimental Research
20. Pharmacotherapy of Alcohol Use Disorders
    Alessandra Buonopane, Ismene L. Petrakis · 2005 · Substance Use & Misuse
21. The risk of cardiovascular complications with current obesity drugs
    Chao, Ariana M., Wadden, Thomas A., Berkowitz, Robert I., Quigley, Kerry, Silvestry, Frank · 2020 · Expert Opinion on Drug Safety
22. Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature
    Lara A. Ray, Andia Heydari, Todd S. Zorick · 2010 · Drug and Alcohol Review
23. Influence of theOPRM1A118G Polymorphism on Alcohol-Induced Euphoria, Risk for Alcoholism and the Clinical Efficacy of Naltrexone
    Elaine Setiawan, Robert O. Pihl, Chawki Benkelfat, Marco Leyton · 2012 · Pharmacogenomics
24. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
    Ralitza V. Gueorguieva, Ran Wu, John Harrison Krystal, Dennis M. Donovan, Stephanie S. O’Malley · 2013 · Addictive Behaviors
25. Effects of naltrexone on cortisol levels in heavy drinkers
    Lara A. Ray, James M. MacKillop, Lorenzo Leggio, Marilee Morgan, Kent E. Hutchison · 2008 · Pharmacology Biochemistry and Behavior
26. Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature
    Shih‐Ku Lin · 2013 · British Journal of Clinical Pharmacology
27. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders
    Sheraz Khoja, Nhat Huynh, Alicia M. P. Warnecke, Liana Asatryan, Michael Walter Jakowec, Daryl L. Davies · 2018 · Psychopharmacology
28. Pharmacotherapy for Alcohol-Related Disorders: What Clinicians Should Know
    John J. Mariani, FRANCES RUDNICK LEVIN · 2004 · Harvard Review of Psychiatry
29. The effects of naltrexone among alcohol non-abstainers: results from the COMBINE study
    Ray, Lara · 2010 · Frontiers in Psychiatry
30. Alcoholics' Evaluations of Alcoholism Treatment
    Alisdair Mackenzie, Richard P. Allen · 2003 · Alcoholism Treatment Quarterly
31. Current and Future Drug Therapies for Alcohol Dependence
    Richard N. Rosenthal · 2006 · Journal of Clinical Psychopharmacology
32. Pruritus in chronic liver disease: Mechanisms and treatment
    Nora V. Bergasa · 2004 · Current Gastroenterology Reports
33. Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals
    Dennis D. Rasmussen, Carrie Kincaid, Janice C. Froehlich · 2015 · Alcoholism Clinical and Experimental Research
34. “It’s about being healthy”; a novel approach to the socio-ecological model using family perspectives within the Latinx community
    Bethany Korom, Meghan Malloy, Caroline Remmers, Mari Cevilla, Kelly Dione, Paula E. Papanek, Jeff Condit, David A. Nelson · 2023 · BMC Public Health
35. What If We Found The Magic Bullet?
    Robin Room · 2006 · Kluwer Academic Publishers eBooks
36. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study
    Gihyun Yoon, Suck Won Kim, PAUL D. THURAS, Joseph John Westermeyer · 2011 · Human Psychopharmacology Clinical and Experimental
37. Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review
    Martyna Sawicka, Derek Kenneth Tracy · 2017 · Therapeutic Advances in Psychopharmacology
38. Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention
    Sarah Siodmok Dermody, Jeffrey D. Wardell, Susan A. Stoner, Christian S. Hendershot · 2018 · Annals of Behavioral Medicine
39. The Lesch alcoholism typology - psychiatric and psychosocial treatment approaches.
    Golda Schlaff, Henriette Walter, Otto Lesch · 2011 · Europe PMC (PubMed Central)
40. Alcohol Craving and Relapse Prediction
    Andreas Heinz, Anne Beck, Jan Mir, Sabine Miriam Grüsser, Anthony A. Grace, Jana Wrase · 2010 · Frontiers in neuroscience
41. Bupropion, Alone and in Combination with Naltrexone, Blunts Binge‐Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57 BL /6J Mice
    Montserrat Navarro, Kendall L. Luhn, Alexey B. Kampov‐Polevoy, James C. Garbutt, Todd E. Thiele · 2019 · Alcoholism Clinical and Experimental Research
42. Extended naltrexone and broad spectrum treatment or motivational enhancement therapy
    Richard Longabaugh, Philip W. Wirtz, Suzy Bird Gulliver, Dena Davidson · 2009 · Psychopharmacology
43. Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
    Mangini, Pratheek, Averill, Lynnette A., Davis, Alan K. · 2022 · Journal of Psychedelic Studies
44. Do Manualized Psychosocial Interventions Help Reduce Relapse among Alcohol‐Dependent Adults Treated with Naltrexone or Placebo? A Meta‐analysis
    Vito Agosti, Edward V. Nunes, Donna O’Shea · 2012 · American Journal on Addictions
45. “Killing Two Birds with One Stone”: Alcohol Use Reduction Interventions with Potential Efficacy at Enhancing Self-control
    Robert Francis Leeman, Devorah Bogart, Lisa M. Fucito, Charlotte A. Boettiger · 2014 · Current Addiction Reports
46. Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence
    Alessandra Matzeu, Lars Y. Terenius, Rémi Martin‐Fardon · 2018 · Alcoholism Clinical and Experimental Research
47. Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis
    Francesca Panin, Alessandra Tiziana Peana · 2019 · Frontiers in Pharmacology
48. Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders
    Sarah G. Helton, Falk W. Lohoff · 2015 · Psychiatry Research
49. Pharmacologic treatment of alcoholism
    Raymond F. Anton, Joseph P. Schacht, Sarah W. Book · 2014 · Handbook of clinical neurology
50. Advancing Pharmacotherapy Development from Preclinical Animal Studies
    Mark Egli · 2018 · Handbook of experimental pharmacology
51. The Treatment of Drinking Problems
    E. Jane Marshall, Keith N. Humphreys, David M. Ball, Griffith Edwards · 2010 · Cambridge University Press eBooks
52. REVIEW: Modulation of high alcohol drinking in the inbred Fawn–Hooded (FH/Wjd) rat strain: implications for treatment
    David H. Overstreet, Amir H. Rezvani, Michael S. Cowen, Feng Chen, Andrew John Lawrence · 2006 · Addiction Biology
53. Does Family History of Alcoholism Moderate Naltrexone's Effects on Alcohol Use?
    Christy Capone, Christopher W. Kahler, Robert M. Swift, Stephanie S. O’Malley · 2011 · Journal of Studies on Alcohol and Drugs
54. Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol‐dependent and polysubstance‐dependent individuals
    Liam J. Nestor, Louise M. Paterson, Anna Murphy, John McGonigle, Csaba Orbán, Laurence John Reed, Eleanor Taylor, Remy Flechais, Dana G. Smith, Edward Thomas Bullmore et al. · 2018 · European Journal of Neuroscience
55. Pharmacological approaches to the management of alcohol addiction.
    Giovanni Addolorato, A Armuzzi, G. Gasbarrini, G. De Lorenzi, C. Ancona, Ludovico Abenavoli, Antonio Parente, Lorenzo Leggio, Esmeralda Capristo, Antonio Greco et al. · 2002 · PubMed
56. Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment
    Keith L. Williams, Jasmine S. Schimmel · 2008 · Alcohol
57. Metacognitive deficits are associated with lower sensitivity to preference reversals in nicotine dependence
    Alexander Soutschek, Adam Bulley, Charlotte E. Wittekind · 2022 · Scientific Reports
58. Drug adjuncts for treating alcohol dependence.
    Gregory B. Collins, M. S McAllister, Kamala Adury · 2006 · Cleveland Clinic Journal of Medicine
59. Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence
    Falk Kiefer, Frank Andersohn, Christian Otte, K. Wolf, Holger Jahn, Klaus Wiedemann · 2004 · Acta Neuropsychiatrica
60. Pharmacogenetically Driven Treatments for Alcoholism
    Albert J. Arias, Richard Andrew Sewell · 2012 · CNS Drugs
61. Charting a path between research and practice in alcoholism treatment.
    Dennis W. McCarty, Eldon Edmundson, Tim Hartnett · 2006 · Europe PMC (PubMed Central)
62. Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism
    Janice C. Froehlich, Stephen M. Fischer, Julian E. Dilley, Emily R. Nicholson, Teal N. Smith, Nick J. Filosa, Logan C. Rademacher · 2016 · Alcoholism Clinical and Experimental Research
63. Preventive Effects of Forced Exercise against Alcohol-induced Physical Dependency and Reduction of Pain Perception Threshold.
    Majid Motaghinejad, Majid Asadi Ghaleni, Ozra Motaghinejad · 2014 · PubMed Central
64. Modeling longitudinal drinking data in clinical trials: An application to the COMBINE study
    Stacia M. DeSantis, Dipankar Bandyopadhyay, Nathaniel L. Baker, Patrick K. Randall, Raymond F. Anton, James J. Prisciandaro · 2013 · Drug and Alcohol Dependence
65. Efficacy and Tolerability of Naltrexone in the Treatment of Alcohol Dependence: Oral versus Injectable Delivery
    Hendrik G. Roozen, Ranne de Waart, Wim van den Brink · 2007 · European Addiction Research
66. Advances in the treatment of craving for alcohol and tobacco
    Peter M. Monti, James M. MacKillop · 2007 · Elsevier eBooks
67. Alcohol addiction and the mu-opioid receptor
    Wade H. Berrettini · 2015 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
68. Rückfallverhinderung bei alkoholabhängigen Männern durch die Kombination von SSRI und kognitiver Verhaltenstherapie
    Martin Hautzinger, Hermann Wetzel, Armin Szegedi, Armin Scheurich, Bernd Lörch, Philipp Singer, Detlef Schläfke, Helmut Sittinger, Thomas Wobrock, Matthias Johannes Müller et al. · 2004 · Der Nervenarzt
69. Co‐Administration of Low‐Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats
    Emily R. Nicholson, Julian E. Dilley, Janice C. Froehlich · 2017 · Alcoholism Clinical and Experimental Research
70. Opioid antagonism modulates wanting-related frontostriatal connectivity
    Alexander Soutschek, Susanna C. Weber, Thorsten Kahnt, Boris B. Quednow, Philippe N. Tobler · 2021 · eLife
71. Los Antagonistas de los Receptores Opioides en el Tratamiento del Alcoholismo
    Josep Guardia Serecigni · 2015 · Adicciones
72. Genetic Basis for Predicting Response to Naltrexone in the Treatment of Alcohol Dependence
    Raymond F. Anton · 2008 · Pharmacogenomics
73. Carisbamate, a Novel Antiepileptic Candidate Compound, Attenuates Alcohol Intake in Alcohol‐Preferring Rats
    Amir H. Rezvani, David H. Overstreet, Anil H. Vaidya, Boyu Zhao, Edward D. Levin · 2009 · Alcoholism Clinical and Experimental Research
74. Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers
    Megan M. Yardley, Michael Mirbaba, Lara A. Ray · 2015 · CNS Drugs
75. Alcohol-Related Disease
    John T. Finnell, David B. McMicken · 2010 · Elsevier eBooks
76. Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice
    Sara Faccidomo, Katarina S. Swaim, Briana L. Saunders, Taruni S. Santanam, Seth M. Taylor, Michelle Kim, Grant T. Reid, Vallari R. Eastman, Clyde W. Hodge · 2018 · Psychopharmacology
77. Naltrexone’s suppressant effects on drinking are limited to the first 3 months of treatment
    Dena Davidson, Philip W. Wirtz, Suzy Bird Gulliver, Richard Longabaugh · 2007 · Psychopharmacology
78. Kappa‐opioid receptors differentially regulate low and high levels of ethanol intake in female mice
    Ashlee Van’t Veer, Karen L. Smith, Bruce M. Cohen, William A. Carlezon, Anita J. Bechtholt · 2016 · Brain and Behavior
79. Alcohol use disorders in women
    Michele G. Cyr, Kelly McGarry · 2002 · Postgraduate Medicine
80. Opioid neuroscience for addiction medicine
    Wade H. Berrettini · 2015 · Progress in brain research
81. Treatments for Alcohol-Related Disorders in China: A Developing Story
    Yi‐lang Tang, Wei Hao, Lorenzo Leggio · 2012 · Alcohol and Alcoholism
82. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence
    Yufei Lin, Henry R. Kranzler, Lindsay A. Farrer, Hongqin Xu, David C. Henderson, Huiping Zhang · 2020 · The Pharmacogenomics Journal
83. Opioid Pharmacogenetics of Alcohol Addiction
    Wade H. Berrettini · 2013 · Cold Spring Harbor Perspectives in Medicine
84. Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence
    María Luisa Gutiérrez García · 2015 · World Journal of Gastroenterology
85. Alcoolodépendance : diagnostic et traitement
    Pascal Perney, H. Rigole, François Blanc · 2007 · La Revue de Médecine Interne
86. An approach to the management of the pruritus of cholestasis
    Nora V. Bergasa · 2004 · Clinics in Liver Disease
87. Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit
    Bernhard Croissant, Karl F Mann · 2004 · psychoneuro
88. Appetitive Needs and Addiction
    Steve Y. Sussman, Sheila Pakdaman · 2020 · Cambridge University Press eBooks
89. Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol‐Preferring (P) Rats
    Janice C. Froehlich, Emily R. Nicholson, Julian E. Dilley, Nick J. Filosa, Logan C. Rademacher, Teal N. Smith · 2017 · Alcoholism Clinical and Experimental Research
90. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study
    Walter Roberts, Julia M. Shi, Jeanette M. Tetrault, Sherry A. McKee · 2018 · Journal of Addiction Medicine
91. Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy
    Claudia Tarli, Antonio Mirijello, Giovanni Addolorato · 2022 · Seminars in Liver Disease
92. Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence
    Kirsten C. Morley, Maree Teesson, Claudia Sannibale, Paul Haber · 2009 · Drug and Alcohol Review
93. Pharmacogenomics in Psychiatric Practice
    Rif S. El‐Mallakh, Rona Jeannie Roberts, Peggy L El-Mallakh, Lillian Findlay, Kristen K. Reynolds · 2016 · Clinics in Laboratory Medicine
94. Attenuation of alcohol withdrawal syndrome and blood cortisol level with forced exercise in comparison with diazepam.
    Majid Motaghinejad, Mohammad Yasan Bangash, Ozra Motaghinejad · 2015 · PubMed
95. An overview of principles of effective treatment of substance use disorders and their potential application to pregnant cigarette smokers
    Sarah Hughes Heil, Teresa Linares Scott, Stephen T. Higgins · 2009 · Drug and Alcohol Dependence
96. A Translational Approach to Novel Medication Development for Protracted Abstinence
    Barbara J. Mason, Amanda E. Higley · 2012 · Current topics in behavioral neurosciences
97. Disulfiram Use in an Elderly Man With Alcoholism and Heart Disease
    Jeff C. Huffman, Theodore A. Stern · 2003 · The Primary Care Companion For CNS Disorders
98. Cannabis Use Disorders
    Perry M. Duncan · 2020 · Cambridge University Press eBooks
99. A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial
    Josep Guardia, Carlos Caso, F. Árias, Antoni Gual, Jordi Sanahuja, Marisa Ram rez, Ildefonso Mengual, Bego a Gonzalvo, Lídia Segura, Joan Trujols et al. · 2002 · Alcoholism Clinical and Experimental Research
100. Neurobiologie der Alkoholabhängigkeit
     Martin K.-H. Schäfer, Andreas Heinz · 2005 · Springer eBooks